Premium
Protection of human gastric mucosa against aspirin—enteric coating or dose reduction?
Author(s) -
* Cole,
; Hudson,
Liew,
Richard M. Murray,
Hawkey,
Heptinstall
Publication year - 1999
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1999.00470.x
Subject(s) - aspirin , medicine , enteric coating , placebo , gastric mucosa , gastroenterology , saline , prostaglandin e2 , prostaglandin , pharmacology , stomach , anesthesia , pathology , dosage form , alternative medicine
Background: Aspirin is widely used for cardiovascular prophylaxis. Aim: To compare the effectiveness of two widely‐used strategies—dose reduction and enteric coating—for the minimization of gastric mucosal injury or toxicity. Methods: Twelve healthy volunteers were studied. On four separate occasions each received, under blinded conditions, five daily doses of plain aspirin 300 mg, plain aspirin 75 mg, enteric‐coated aspirin 300 mg or placebo. Ex vivo prostaglandin E 2 synthesis was stimulated by the vortex mixing of gastric mucosal biopsies in Tris saline and measured by radioimmunoassay. Mucosal injury was quantified both by counting erosions and with a visual analogue scale. Results: All three preparations reduced prostaglandin E 2 synthesis by day five, by (median) 84% for plain aspirin 300 mg, by 80% for enteric coated aspirin 300 mg and by 63% for plain aspirin 75 mg. There was little mucosal injury prior to the start of each dose and period and no significant change with placebo. Plain aspirin caused a dose‐dependent mucosal injury, with two (median, IQR 0–7) gastric erosions after five days of plain aspirin 75 mg, and 18 (2–26) after five days of plain aspirin 300 mg. With enteric‐coated aspirin 300 mg there were 0 (0–1) gastric erosions ( P = 0.003 compared to plain aspirin 300 mg P = 0.11, compared to plain aspirin 75 mg). Conclusion: Enteric coated aspirin reduces acute gastric mucosal injury to placebo levels, despite its inhibition of prostaglandin synthesis. Enteric coating is an appropriate strategy for the prevention of gastric mucosal damage induced by low‐dose aspirin, which warrants systematic clinical evaluation.